New trial data point to longer-lasting mobility gains, expanding options for patients stuck between early damage and full joint replacement.
A particular kind of frustration that comes with knee problems. You’re not “bad enough” for a replacement, but you’re far from fine. You start skipping runs, avoiding stairs and sitting out games you used to enjoy. Life doesn’t stop; it just quietly shrinks.
For years, medicine hasn’t had a clean answer for this in-between stage. Standard procedures can smooth things over, but often don’t last. Full replacements, meanwhile, are held back for later, when damage becomes severe.
New five-year data from Smith+Nephew suggest that the gap (long ignored) might finally be getting real attention.
In results published in the American Journal of Sports Medicine, the company’s CARTIHEAL AGILI-C cartilage repair implant outperformed traditional surgical approaches across every measured time point up to five years [1]. That includes less pain, better mobility and improved day-to-day function – the things that actually define whether someone feels “okay” again.
“Notably, CARTIHEAL patients had twice the reduction in pain scores compared to standard care,” said Dr Andreas Gomoll, Professor of Orthopedic Surgery at Weill-Cornell Medical School and Attending Orthopedic Surgeon at the Hospital for Special Surgery in New York. “What excites me even more is that these outcomes were comparable for both patients with and without osteoarthritis.”
Traditionally, once osteoarthritis enters the picture, even in its earlier stages, treatment options narrow fast. Many clinical trials exclude these patients altogether. In practice, they’re often told to manage symptoms and wait.
So what’s different here? The AGILI-C implant doesn’t replace the knee. It helps rebuild it or at least gives the body a better shot at doing so. Think of it as a scaffold placed into the damaged area of the joint. Made from aragonite, a naturally occurring mineral, it serves as a temporary framework for new cartilage and underlying bone to grow. Instead of scraping or drilling the area, as standard procedures often do, it tries to restore the structure. It’s a shift in philosophy: from “patch and manage” to “support and regenerate.”
Moreover, the data suggest that the shift may be sticking. Patients maintained improvements over the full five-year period, with better overall outcomes and fewer treatment failures compared to standard care.
If there’s a headline within the headline, it’s this: the implant appears to work just as well in patients with mild to moderate osteoarthritis as it does in those without it. That matters because this group is large and historically underserved.
“This represents a vital new option for those in the osteoarthritis treatment gap where cartilage is too damaged for standard repair but not enough for joint replacement,” Gomoll added. It’s a group that has long lived in medical limbo. Too early for the “big fix”, too complex for the small ones.
Professor Elizaveta Kon of Humanitas Research Hospital characterized the findings more directly, asserting that the medical community can finally provide a dependable, evidence-based solution for a significant number of patients who previously faced limited treatment options. She further expressed genuine excitement about the observation of such lasting, durable results in the study population.
Also, the investment angle here is hard to miss. The implant is already FDA-approved and commercially available in the US, with a relatively broad indication, meaning more patients are eligible than with many existing cartilage repair techniques. That alone expands its potential reach.
Then there’s the system-level shift: a Category I CPT code for the procedure is set to take effect in January 2027. It sounds bureaucratic, but it’s critical. Reimbursement often determines whether a promising technology actually gets used in real clinics.
For Smith+Nephew, it strengthens a broader strategy: investing in technologies that delay or reduce the need for more invasive interventions, while still improving outcomes in the near term.
The bigger picture: mobility as longevity. How medicine is starting to treat the “middle years” of degeneration – not as something to endure, but as something to intervene in. Earlier, smarter and hopefully more durable.
Mobility sits at the center of that. When movement declines, everything else tends to follow: physical health, independence, even social connection. It’s one of the clearest fault lines in aging.
What technologies like AGILI-C suggest is that we may be getting better at holding that line by extending the life of what’s already there, by buying people more years of movement that feels natural.
